DBV Technologies (DBVT) Cash from Financing Activities (2020 - 2026)
DBV Technologies (DBVT) posted quarterly Cash from Financing Activities of $100000.0 for Q2 2026, down 99.91% year-on-year from $117.0 million in Q2 2025, and down 99.89% on a QoQ basis from $88.9 million in Q1 2026.
DBV Technologies (DBVT) Cash from Financing Activities (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Cash from Financing Activities for 7 consecutive years, with $100000.0 the latest figure, recorded in Q2 2026.
- Quarterly Cash from Financing Activities fell 99.91% year-over-year to $100000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $248.2 million (up 110.89% YoY) and the FY2025 annual result came in at $276.2 million, up 46949.74% from the prior year.
- Cash from Financing Activities fell to $100000.0 in Q2 2026 per DBVT's latest filing, from $88.9 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for DBVT reached as high as $195.4 million in Q2 2022 and fell as low as -$837000.0 in Q3 2023.
- A 5-year average of $33.3 million and a median of $7000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities sank 342.86% — and 2025, when it surged 354645.45%.
- Year by year, Cash from Financing Activities stood at -$283000.0 in 2022, then jumped by 33.22% to -$189000.0 in 2023, then soared by 457.14% to $675000.0 in 2024, then soared by 23464.44% to $159.1 million in 2025, then plunged by 99.94% to $100000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $100000.0, $88.9 million, and $159.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100,000.00 |
| Jun 30, 2026 | 100,000.00 |
| Mar 31, 2026 | 88.90 Mn |
| Mar 31, 2026 | 88.90 Mn |
| Dec 31, 2025 | 159.06 Mn |
| Dec 31, 2025 | 159.06 Mn |
| Sep 30, 2025 | 122,000.00 |
| Sep 30, 2025 | 122,000.00 |
| Jun 30, 2025 | 117.00 Mn |
| Jun 30, 2025 | 117.00 Mn |
| Dec 31, 2024 | 675,000.00 |
| Dec 31, 2024 | 675,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Sep 30, 2024 | 7,000.00 |
| Jun 30, 2024 | -33,000.00 |
| Jun 30, 2024 | -33,000.00 |
| Mar 31, 2024 | -62,000.00 |
| Mar 31, 2024 | -62,000.00 |
| Dec 31, 2023 | -189,000.00 |
| Dec 31, 2023 | -189,000.00 |